PE20180520A1 - Compuestos antibacterianos - Google Patents

Compuestos antibacterianos

Info

Publication number
PE20180520A1
PE20180520A1 PE2017002738A PE2017002738A PE20180520A1 PE 20180520 A1 PE20180520 A1 PE 20180520A1 PE 2017002738 A PE2017002738 A PE 2017002738A PE 2017002738 A PE2017002738 A PE 2017002738A PE 20180520 A1 PE20180520 A1 PE 20180520A1
Authority
PE
Peru
Prior art keywords
aromatic
ring
antibacterial compounds
membered
compounds
Prior art date
Application number
PE2017002738A
Other languages
English (en)
Spanish (es)
Inventor
Magali Madeleine Simone Motte
Pierre Jean-Marie Bernard Raboisson
Abdellah Tahri
Jerôme Emile Georges Guillemont
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56289523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180520(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of PE20180520A1 publication Critical patent/PE20180520A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PE2017002738A 2015-07-02 2016-07-01 Compuestos antibacterianos PE20180520A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15174936 2015-07-02
EP16174718 2016-06-16
EP16174713 2016-06-16

Publications (1)

Publication Number Publication Date
PE20180520A1 true PE20180520A1 (es) 2018-03-14

Family

ID=56289523

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002738A PE20180520A1 (es) 2015-07-02 2016-07-01 Compuestos antibacterianos

Country Status (29)

Country Link
US (6) US20180155341A1 (en:Method)
EP (3) EP4074378A1 (en:Method)
JP (3) JP7099824B2 (en:Method)
KR (2) KR102710552B1 (en:Method)
CN (3) CN108235704B (en:Method)
AU (3) AU2016287478B2 (en:Method)
BR (1) BR112017028318B1 (en:Method)
CA (2) CA2986326A1 (en:Method)
CL (1) CL2017003404A1 (en:Method)
CO (1) CO2017013408A2 (en:Method)
DK (1) DK3316969T3 (en:Method)
EA (2) EA201890201A1 (en:Method)
ES (1) ES2914681T3 (en:Method)
HK (1) HK1249468A1 (en:Method)
HR (1) HRP20220339T1 (en:Method)
IL (2) IL256379A (en:Method)
LT (1) LT3316969T (en:Method)
MA (1) MA42293A (en:Method)
MD (1) MD3316969T2 (en:Method)
MX (2) MX2017016789A (en:Method)
PE (1) PE20180520A1 (en:Method)
PH (2) PH12017502298A1 (en:Method)
PL (1) PL3316969T3 (en:Method)
RS (1) RS63201B1 (en:Method)
SI (1) SI3316969T1 (en:Method)
SM (1) SMT202200220T1 (en:Method)
UA (1) UA125171C2 (en:Method)
WO (2) WO2017001660A1 (en:Method)
ZA (1) ZA201708692B (en:Method)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108601B (zh) 2014-08-28 2021-08-20 阿森纽荣股份公司 糖苷酶抑制剂
SG10201913880XA (en) 2015-07-02 2020-03-30 Hoffmann La Roche Bicyclic lactams and methods of use thereof
BR112017028318B1 (pt) * 2015-07-02 2024-02-20 Janssen Sciences Ireland Uc Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação
PE20181352A1 (es) 2015-09-17 2018-08-22 Marvin J Miller Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
CA3014572C (en) 2016-02-25 2023-10-03 Asceneuron S.A. Acid addition salts of piperazine derivatives
US10556902B2 (en) 2016-02-25 2020-02-11 Asceneuron Sa Glycosidase inhibitors
KR20180132629A (ko) 2016-02-25 2018-12-12 아셰뉴론 에스아 글리코시다제 저해제
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
EP3472158A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
CN109843886B (zh) 2016-10-17 2022-04-19 豪夫迈·罗氏有限公司 二环吡啶酮内酰胺及其使用方法
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
JP2020506940A (ja) * 2017-02-06 2020-03-05 ヤンセン ファーマシューティカ エヌ．ベー． Ｏｇａ阻害化合物
EA201991997A1 (ru) * 2017-03-01 2020-01-22 Янссен Сайенсиз Айрлэнд Анлимитед Компани Комбинированная терапия
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
TW201920170A (zh) * 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
WO2019079410A1 (en) 2017-10-17 2019-04-25 Vanderbilt University ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4
EP3732163A4 (en) 2017-12-20 2021-07-14 Vanderbilt University MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
RU2680972C1 (ru) * 2018-02-13 2019-03-01 Федеральное государственное бюджетное научное учреждение "Центральный научно-исследовательский институт туберкулеза" Способ определения длительности химиотерапии туберкулеза органов дыхания с множественной и широкой лекарственной устойчивостью МБТ у детей и подростков
WO2019175737A1 (en) * 2018-03-12 2019-09-19 University Of Notre Dame Du Lac Deuterated imidazopyridines
CN112074519B (zh) 2018-04-20 2024-08-02 豪夫迈·罗氏有限公司 作为rip1激酶抑制剂用于治疗例如肠易激综合征(ibs)的化合物
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
PL3841093T3 (pl) 2018-08-22 2023-12-11 Asceneuron Sa Sole addycyjne kwasu bursztynowego lub kwasu fumarowego z pochodnymi piperazyny użyteczne jako inhibitory glikozydazy
US11731972B2 (en) 2018-08-22 2023-08-22 Asceneuron Sa Spiro compounds as glycosidase inhibitors
WO2020039027A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Pyrrolidine glycosidase inhibitors
CN109503631A (zh) * 2018-12-29 2019-03-22 中国医学科学院医药生物技术研究所 含有二氮杂螺环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法和应用
US20220235047A1 (en) * 2019-05-28 2022-07-28 Shionogi & Co., Ltd. A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE
KR102076958B1 (ko) 2019-06-24 2020-02-13 엘티소재주식회사 헤테로고리 화합물 및 이를 이용한 유기 발광 소자
TWI861208B (zh) 2019-09-10 2024-11-11 日商鹽野義製藥股份有限公司 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物
EP4028399B1 (en) 2019-09-13 2024-02-14 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
JP2022550784A (ja) 2019-09-30 2022-12-05 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー ４－キノリノン抗菌化合物
WO2021063915A1 (en) 2019-09-30 2021-04-08 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2021130732A1 (en) 2019-12-27 2021-07-01 TECNIMEDE - Sociedade Técnico-medicinal, SA Antibacterial quinolines
WO2022194803A1 (en) 2021-03-16 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
US20240199651A1 (en) 2021-03-17 2024-06-20 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
BR112023018654A2 (pt) 2021-03-17 2023-10-03 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
WO2022214519A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214520A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
US20240279217A1 (en) 2021-06-29 2024-08-22 TECNIMEDE - Sociedade Técnico-medicinal, SA Heterocyclic compounds for the treatment of tuberculosis
JP2024540052A (ja) 2021-10-28 2024-10-31 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 細菌感染の治療に使用するためのイミダゾピリジンアミド及び関連化合物
CN114957954B (zh) * 2022-05-16 2024-08-20 万华化学集团股份有限公司 一种用于光学透镜的热塑性树脂组合物及其制备方法和应用
WO2023244764A1 (en) * 2022-06-15 2023-12-21 C4 Therapeutics, Inc. Compounds for the targeted degradation of smarca2
TW202409040A (zh) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025017047A1 (en) 2023-07-18 2025-01-23 Janssen Pharmaceutica Nv Combination products of at least three antibiotics comprising bedaquiline, pretomanid or delamanid, and a cytochrome bc1 inhibitor, and their use in the treatment of mycobacterial infections
WO2025129116A1 (en) * 2023-12-14 2025-06-19 C4 Therapeutics, Inc. Compounds for the targeted degradation of smarca2

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9703543A (es) 1994-11-15 1997-08-30 Upjohn Co Antibacterianos de oxazina biciclica y oxazolidinona tiazina.
PT828741E (pt) 1995-05-11 2002-02-28 Upjohn Co Oxazolidinonas de diazinilo espirociclico e biciclico e de carbazinilo
NZ538391A (en) 2002-07-25 2005-10-28 Janssen Pharmaceutica Nv Quinoline derivatives and their use as mycobacterial inhibitors
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
MA27360A1 (fr) 2004-11-23 2005-06-01 Brahim Bennani Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux
CN101631786A (zh) 2006-12-20 2010-01-20 先灵公司 新颖的jnk抑制剂
TW200901969A (en) * 2007-06-06 2009-01-16 Smithkline Beecham Corp Chemical compounds
TWI498115B (zh) 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
BRPI0909028A2 (pt) 2008-03-26 2015-09-22 Global Alliance For Tb Drug Dev nitroimidazóis bicíclicos covalentemente ligados a fenil oxazolidinonas substituídas, composições farmacêuticas e uso dos mesmos
AU2009294850B2 (en) 2008-09-22 2015-07-02 Oregon Health & Science University Methods for detecting a Mycobacterium tuberculosis infection
AU2009334997A1 (en) 2008-12-30 2011-08-04 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as Raf kinase inhibitors
CN102762556B (zh) 2009-11-05 2017-04-26 圣母大学 咪唑并[1,2‑a]吡啶类化合物及其合成及使用方法
NZ602311A (en) * 2010-03-18 2014-08-29 Pasteur Institut Korea Anti-infective compounds
US9029389B2 (en) 2011-04-21 2015-05-12 Institut Pasteur Korea Anti-inflammation compounds
EA026152B1 (ru) 2011-09-01 2017-03-31 Новартис Аг СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ с-kit
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
AU2012302176A1 (en) 2011-09-01 2014-04-17 Irm Llc Compounds and compositions as c-kit kinase inhibitors
US9822129B2 (en) * 2012-03-02 2017-11-21 Genentech, Inc. Amido spirocyclic amide and sulfonamide derivatives
KR101918469B1 (ko) 2012-06-04 2018-11-15 한국화학연구원 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
AU2013292529A1 (en) * 2012-07-18 2015-02-12 Marvin J. Miller 5,5-heteroaromatic anti-infective compounds
KR101650716B1 (ko) 2012-11-22 2016-08-24 한국화학연구원 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물
HUE056198T2 (hu) * 2013-08-02 2022-02-28 Pasteur Institut Korea Fertõzés elleni vegyületek
KR101564425B1 (ko) 2013-11-26 2015-10-30 한국화학연구원 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물
CN105524058B (zh) 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
JP2017533220A (ja) 2014-11-03 2017-11-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 結核処置のための多剤療法
BR112017028318B1 (pt) 2015-07-02 2024-02-20 Janssen Sciences Ireland Uc Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação
CN109415349A (zh) 2016-06-16 2019-03-01 爱尔兰詹森科学公司 杂环化合物作为抗细菌剂
EP3472158A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
EA201991997A1 (ru) 2017-03-01 2020-01-22 Янссен Сайенсиз Айрлэнд Анлимитед Компани Комбинированная терапия

Also Published As

Publication number Publication date
MD3316969T2 (ro) 2022-07-31
NZ774761A (en) 2024-09-27
JP2018519302A (ja) 2018-07-19
CO2017013408A2 (es) 2018-05-31
NZ737408A (en) 2024-07-26
AU2016287477A1 (en) 2017-11-30
US20230014173A1 (en) 2023-01-19
US20240132470A1 (en) 2024-04-25
IL256379A (en) 2018-02-28
JP7516338B2 (ja) 2024-07-16
WO2017001661A1 (en) 2017-01-05
EP4074378A1 (en) 2022-10-19
MA42293A (fr) 2018-05-09
KR20180022826A (ko) 2018-03-06
AU2016287478B2 (en) 2021-10-21
US10364232B2 (en) 2019-07-30
US11866419B2 (en) 2024-01-09
EA201890201A1 (ru) 2018-06-29
LT3316969T (lt) 2022-03-25
KR102710552B1 (ko) 2024-09-25
CN107708809A (zh) 2018-02-16
EP3316969B1 (en) 2022-03-02
RS63201B1 (sr) 2022-06-30
KR20180022833A (ko) 2018-03-06
IL256391B (en) 2021-03-25
US20200239434A1 (en) 2020-07-30
AU2016287478A1 (en) 2017-11-30
CA2986326A1 (en) 2017-01-05
WO2017001660A1 (en) 2017-01-05
PL3316969T3 (pl) 2022-06-20
HK1249468A1 (zh) 2018-11-02
PH12017502297A1 (en) 2018-06-25
CN113980015A (zh) 2022-01-28
CA2986331A1 (en) 2017-01-05
EP3316968A1 (en) 2018-05-09
EP3316969A1 (en) 2018-05-09
US20180186768A1 (en) 2018-07-05
BR112017028318A2 (pt) 2018-09-04
HRP20220339T1 (hr) 2022-05-13
PH12017502298B1 (en) 2018-06-11
CN108235704B (zh) 2021-10-26
IL256391A (en) 2018-02-28
ZA201708692B (en) 2024-07-31
CL2017003404A1 (es) 2018-05-11
CN108235704A (zh) 2018-06-29
US20190330189A1 (en) 2019-10-31
AU2022200385B2 (en) 2024-06-13
PH12017502298A1 (en) 2018-06-11
JP2018524339A (ja) 2018-08-30
BR112017028318B1 (pt) 2024-02-20
SMT202200220T1 (it) 2022-07-21
MX386598B (es) 2025-03-19
JP7099824B2 (ja) 2022-07-12
HK1254677A1 (zh) 2019-07-26
MX2017016788A (es) 2018-07-06
DK3316969T3 (da) 2022-05-02
JP2022043078A (ja) 2022-03-15
MX2017016789A (es) 2018-06-11
US11180472B2 (en) 2021-11-23
US20180155341A1 (en) 2018-06-07
EA201890204A1 (ru) 2018-06-29
ES2914681T3 (es) 2022-06-15
SI3316969T1 (sl) 2022-05-31
AU2022200385A1 (en) 2022-02-17
UA125171C2 (uk) 2022-01-26
AU2016287477B2 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
PE20180520A1 (es) Compuestos antibacterianos
CL2020003260A1 (es) Compuestos de naftiridinona sustituidos útiles como activadores de células t
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
UY38428A (es) Nuevos compuestos antihelmínticos
MX2021009673A (es) Moduladores de ror-gamma.
DOP2022000066A (es) Moduladores de sting (estimulador de genes de interferón)
MX2023011675A (es) Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia.
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
CL2018000070A1 (es) Modulares de diaciglicerol aciltransderasa 2 (dgta2)
PE20181074A1 (es) Compuestos heteroaromaticos como inhibidores de btk
MA40281A (fr) Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
CR20170605A (es) DERIVADOS DE 3-TETRAZOLIL-BENCENO-1,2-DISULFONAMIDA COMO INHIBIDORES DE METALO -ß-LACTAMASA
CL2021001461A1 (es) Moduladores de trex1
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
NI202000058A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
PE20170120A1 (es) Compuestos novedosos de pirimidina sustituidos
BR112017019731A2 (pt) compostos heterocíclicos tricíclicos úteis como inibidores de tnf
CL2020001147A1 (es) Compuestos antibacterianos
CL2019003037A1 (es) Combinaciones fungicidas.
BR112017019773A2 (pt) compostos heterocíclicos tricíclicos substituídos
MY202753A (en) Griseofulvin compound and pharmaceutical use thereof
PE20200333A1 (es) Compuestos y metodos para tratar infecciones bacterianas
MX2019006768A (es) Peptidos antimicrobianos.